Survivin、P16和CyclinD1在卵巢癌的表达及临床意义

目的探讨卵巢上皮性癌组织中抑凋亡蛋白Survivin，P16基因和细胞周期素蛋白CyclinD1的表达及临床意义。方法采用免疫组织化学SABC法检测18例良性卵巢肿瘤、20例交界性卵巢肿瘤、58例卵巢上皮性癌及10例正常卵巢组织中的Survivin，P16和CyclinD1表达及其与临床病理的关系。结果Survivin在上皮性卵巢良性肿瘤，交界性肿瘤和恶性肿瘤组织中的检出率为：16．7％、40．0％、62．1％，在正常卵巢组织无阳性表达。P16蛋白在正常卵巢组织中的检出率为80．0％，卵巢良性肿瘤，交界性肿瘤，恶性肿瘤的检出率分别为：61．1％、50．0％、22．4％。CyclinD1在正常卵巢组织中的检出率为10．0％，卵巢良性肿瘤，交界性肿瘤和恶性肿瘤组织中CyclinD1蛋白的阳性检测率分别为27．8％、45．0％、58．6％。结论对Survivin，P16和CyclinD1表达的检测有助于判断卵巢癌预后，指导临床治疗，并为基因治疗提供理论依据。

Expression of Survivin,P16 and CyclinD1 in ovarian epithelial tumors and their clinical significances

Objective To investigate the expression of Survivin,p16 and CyclinD1 in ovarian epithelial tumors and their clinical significances. Methods Using immunohistochemical method SABlE,the author examined Survivin,pl 6 and CyclinD1 in 18 cases benign, 20 borderline, 58 malignant tumors and 10 normal ovarian tissues. Results The expression of Survivin in ovarian epithelial tumors, benign tumor, borderline tumor, malignant tumor tissue was 16.7 %,40.0 %,62.1%, the expression of Survivin in normal ovarian has no connection. The expression of Survivin in normal ovarian,ovarian epithelial benign tumor,borderline tumor and malignant tumor tissue was 80.0% ,61.1% ,50.0% and 22.4%, respectively. The expression of CyclinD1 in ovarian epithelial tumors, benign tumor, borderline tumor, malignant tumor and normal ovarian tissue was 27.8% ,45.0% ,58.6% and 10.0%. Conclusions Measurement of the expression of Survivin, P16 and CyclinD1 in patients＇ tumors might help in predicting prognosis,directing clinical treatment and providing theories for genetic therapy.